Venture capitalists from the U.S. and other countries have reduced investment in Chinese drugmakers, denting momentum in China’s developing biotechnology industry.
Venture capitalists from the U.S. and other countries have reduced investment in Chinese drugmakers, denting momentum in China’s developing biotechnology industry.